Open study of SGP2 for myopia and myopic astigmatism

Open study of SGP2 for myopia and myopic astigmatism - Open study of SGP2 for myopia and myopic astigmatism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038182

Enrollment

Registered

2019-10-03

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia and myopic astigmatism

Interventions

Over 13weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) =>20 years of age on the day of signing the informed consent. (2) Patient who understands the gist of the clinical trial and who has signed the Informed Consent Form with his / her free will (3) Patient with myopic or myopic astigmatic eyes that require vision correction in both eyes

Exclusion criteria

Exclusion criteria: (1) Patient who have the following eye symptoms in one or both eyes. - Acute or subacute inflammation of the anterior segment - Eye infection - Uveitis - Eyelid abnormalities

Design outcomes

Primary

Measure	Time frame
Safety(13 weeks after first day the subect used)	—

Countries

Japan

Contacts

Public ContactHideki Tojima

ROHTO pharmaceutical CO.,LTD Clinical Development Division

tojima@rohto.co.jp0774-71-8820

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026